Want to see TIL full AI Analyst Report?
Instil Bio (TIL) AI Stock Analysis
Instil Bio
(NASDAQ:TIL)
The score is primarily weighed down by weak financial performance (no revenue, continued losses, negative free cash flow, and declining equity), despite clear multi-year improvement in losses and cash burn and a low-debt balance sheet. Technicals are mixed with modest short-term strength but a broader downtrend, and valuation support is limited by negative earnings and no dividend yield.
Instil Bio (TIL) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $47.41M
- Dividend Yield
- ―
- Average Volume (3M)
- 28.89K
- Price to Earnings (P/E)
- -1.6
- Beta (1Y)
- 1.24
- Revenue Growth
- ―
- EPS Growth
- 65.39%
- Country
- US
- Employees
- 17
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Instil Bio Business Overview & Revenue Model
Company Description
Instil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities. It seeks to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need. Inst...
Instil Bio Financial Statement Overview
Summary
Development-stage profile with essentially no revenue and ongoing losses. Results are improving (net loss and cash burn have narrowed materially over multiple years), and leverage is low (minimal debt versus equity), but the company still has negative operating/FCF and a steadily shrinking equity base, indicating continued financing risk.
Income Statement
18Very NegativeBalance Sheet
54NeutralCash Flow
33Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -24.00K | -534.00K | 0 | 0 | -5.99M | 0 |
| EBITDA | -29.60M | -65.01M | -62.53M | -147.12M | -217.38M | -152.51M |
| Net Income | -30.28M | -71.37M | -74.14M | -156.09M | -223.18M | -156.79M |
Balance Sheet | ||||||
| Total Assets | 197.71M | 203.52M | 263.57M | 325.63M | 482.13M | 609.98M |
| Cash, Cash Equivalents and Short-Term Investments | 69.68M | 76.13M | 113.31M | 150.36M | 260.92M | 454.10M |
| Total Debt | 3.67M | 85.18M | 86.89M | 86.05M | 79.90M | 0 |
| Total Liabilities | 90.33M | 89.66M | 94.13M | 99.80M | 118.52M | 54.78M |
| Stockholders Equity | 107.38M | 113.87M | 169.44M | 225.83M | 363.61M | 555.20M |
Cash Flow | ||||||
| Free Cash Flow | -23.61M | -36.62M | -65.70M | -102.69M | -264.75M | -179.97M |
| Operating Cash Flow | -23.61M | -36.62M | -55.70M | -82.03M | -180.16M | -122.14M |
| Investing Cash Flow | 21.24M | 25.48M | 53.97M | 41.13M | 114.54M | -474.40M |
| Financing Cash Flow | 378.00K | 7.29M | 1.75M | 8.08M | 71.89M | 393.16M |
Instil Bio Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TIL, the sentiment is Neutral. The current price of 6.83 is above the 20-day moving average (MA) of 6.28, below the 50-day MA of 6.89, and below the 200-day MA of 7.68, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 58.75 is Neutral, neither overbought nor oversold. The STOCH value of 84.73 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TIL.
Instil Bio Risk Analysis
Instil Bio disclosed 70 risk factors in its most recent earnings report. Instil Bio reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksInstil Bio Peers Comparison
Overall Rating
- TIL46Neutral
ALXO42Neutral
ZNTL40Underperform
TCRX39Underperform
SRZN36Underperform
NKTX27Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| TIL | 46Neutral | $47.41M | -1.56 | -26.78% | ― | ― | 65.39% |
| ALXO | 42Neutral | $188.06M | -1.02 | -90.30% | ― | ― | 48.20% |
| ZNTL | 40Underperform | $166.62M | -0.69 | -87.95% | ― | -100.00% | 14.08% |
| TCRX | 39Underperform | $14.23M | -0.20 | -108.72% | ― | 2.15% | 17.34% |
| SRZN | 36Underperform | $372.00M | -0.70 | 187.62% | ― | -8.79% | -195.46% |
| NKTX | 27Underperform | $123.91M | -0.91 | -39.64% | ― | ― | -6.70% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TIL | Instil Bio, Inc. | 6.83 | -7.98 | -53.88% | |
| ZNTL | Zentalis Pharmaceuticals Inc | 1.72 | 0.40 | 30.30% | |
| NKTX | Nkarta, Inc. | 1.73 | -0.23 | -11.73% | |
| ALXO | Alx Oncology Holdings, Inc. | 1.16 | -0.11 | -9.06% | |
| SRZN | Surrozen, Inc. | 31.00 | 19.20 | 162.71% | |
| TCRX | Tscan Therapeutics, Inc. | 0.19 | -0.90 | -82.75% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 29, 2026